Current perspectives in therapeutic myocardial angiogenesis.
The complex mechanisms mediating the development of new blood vessels are now beginning to be unraveled. In conjunction with major biotechnology advances, this has facilitated the initiation of translational research related to a novel treatment strategy for patients with myocardial or leg ischemia due to obstructive arterial disease--therapeutic angiogenesis. At present, at least 17 clinical trials of myocardial angiogenesis have been presented involving over 900 patients. Uncertainty exists as to the optimal delivery route and angiogenic agent, and this uncertainty is reflected in the diverse methodology of the trials published thus far. The majority of patients received an angiogenic protein via the intracoronary route. Other delivery techniques--such as direct intramyocardial injection via transepicardial or transendocardial routes--and other angiogenic agents, including master genes, have also been studied. Most recently, interest has grown in the potential angiogenesis effects of cell therapy--such as autologous bone marrow cells or cultured stem cells--and there are now several groups initiating Phase I/II trials in this area. This review summarizes the current evidence pertaining to the safety, feasibility, and efficacy of various angiogenic techniques aimed at enhancing myocardial blood flow and alleviating angina.
Kinnaird
Tim
T
Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center, 110 Irving St. NW, Suite 4B-1, Washington, DC 20010, USA. tim.kinnaird@medstar.net
Stabile
Eugenio
E
Epstein
Stephen E
SE
Fuchs
Shmuel
S
D043925:Angiogenesis Inducing Agents / Q000008:administration & dosage*; D064987:Cell- and Tissue-Based Therapy; D003327:Coronary Disease / Q000628:therapy*; D006801:Humans
D043925:Angiogenesis Inducing Agents